The aim of adjuvant therapy in breast cancer is to reduce the risk of recurrence. Some patients develop metastases many years after apparently successful treatment of their primary cancer. Tumour dormancy may explain the long time between initial diagnosis and treatment of cancer, and occurrence of relapse. The regulation of the switch from clinical dormancy to cancer regrowth in locoregional and distant sites is poorly understood. In this review, we report some data supporting the existence of various factors that may explain cancer dormancy including genetic and epigenetic changes, angiogenic switch, microenvironment, and immunosurveillance. A better definition and understanding of these factors should allow the identification of patients at high risk of relapse and to develop new therapeutic strategies in order to improve prognosis.
Tumour dormancy and clinical implications in breast cancer / L. Gelao, C. Criscitiello, L. Fumagalli, M. Locatelli, S. Manunta, A. Esposito, I. Minchella, A. Goldhirsch, G. Curigliano. - In: ECANCERMEDICALSCIENCE. - ISSN 1754-6605. - 7:1(2013), pp. 320.1-320.15. [10.3332/ecancer.2013.320]
Tumour dormancy and clinical implications in breast cancer
C. Criscitiello;G. CuriglianoWriting – Original Draft Preparation
2013
Abstract
The aim of adjuvant therapy in breast cancer is to reduce the risk of recurrence. Some patients develop metastases many years after apparently successful treatment of their primary cancer. Tumour dormancy may explain the long time between initial diagnosis and treatment of cancer, and occurrence of relapse. The regulation of the switch from clinical dormancy to cancer regrowth in locoregional and distant sites is poorly understood. In this review, we report some data supporting the existence of various factors that may explain cancer dormancy including genetic and epigenetic changes, angiogenic switch, microenvironment, and immunosurveillance. A better definition and understanding of these factors should allow the identification of patients at high risk of relapse and to develop new therapeutic strategies in order to improve prognosis.File | Dimensione | Formato | |
---|---|---|---|
can-7-320.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
2.05 MB
Formato
Adobe PDF
|
2.05 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.